Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study
Various studies have reported that there has been a decrease in IL-6 level, C-reactive protein (CRP) level, and lower risk of death with the use of tocilizumab in patients with severe COVID-19 disease. [5] Therefore, cytokine storm has an important role in disease progression with the viral invasion...
Gespeichert in:
| Veröffentlicht in: | National journal of physiology, pharmacy and pharmacology pharmacy and pharmacology, 2021-01, Vol.11 (9), p.1060-1063 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1063 |
|---|---|
| container_issue | 9 |
| container_start_page | 1060 |
| container_title | National journal of physiology, pharmacy and pharmacology |
| container_volume | 11 |
| creator | Ismail, Teli Shaikh Emaran Shaikh Ramanand, Jaiprakash Mandhare, Rajshree Netram Bhangale, Chetan Suresh |
| description | Various studies have reported that there has been a decrease in IL-6 level, C-reactive protein (CRP) level, and lower risk of death with the use of tocilizumab in patients with severe COVID-19 disease. [5] Therefore, cytokine storm has an important role in disease progression with the viral invasion of the cellular immunity. [...]immunomodulatory agents may play an important role in handling the immune response. Studies have reported there has been a decrease in IL-6 level, C-reactive protein (CRP) level, and lower risk of death with the use of tocilizumab in patients with severe COVID-19 disease. [6,7] Tocilizumab (Actemra®) is a recombinant IL-6 receptor monoclonal antibody which can specifically bind to the membrane-bound IL-6 receptor and soluble IL-6 receptor. [...]it inhibits signal transduction and prevents further damage due to immune response. [9] Despite so many studies, it is not claimed that tocilizumab has a positive therapeutic effect on COVID-19. [...]this study aims to assess the effect of tocilizumab on clinical outcomes in terms of death and discharge in patients who received tocilizumab at our institution. |
| doi_str_mv | 10.5455/njppp.<SERIAL_printed_date>2021</SERIAL_printed_date>.11.05156<SERIAL_printed_date>2021</SERIAL_printed_date>0506<SERIAL_printed_date>2021</SERIAL_printed_date> |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2572292338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2572292338</sourcerecordid><originalsourceid>FETCH-proquest_journals_25722923383</originalsourceid><addsrcrecordid>eNqVTc1KAzEQDqJg0b7DgOduk-xma6UIpbZYEAQVr0u6GWmW7SYmsxV9Bh_ExzSCRw92Lt98fH-MfQmeqUKpcdd477PZ4_JhPb-rfLAdoamMJryWXIrZ-C8lEyLjSqjywBxX_NDIERtImYtRLnl5nP6Eo6KcyFM2jLHh6aaFSI4B-1y0trO1bsH1VLsdgu2gdsF1em9DH8HYiDoieE0WO4pAAdOEgTdLWyBX29Z-9Du9AU2gwaBJbT_64v55fQNbF70l3V7BHAJSSBRrsnsEt4kY9qk1TbUQqTfv5-zkRbcRh794xi5Wy6fF7cgH99pjpKpxfUj2WEk1kXIq8_wy_5_rGzcvjyY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2572292338</pqid></control><display><type>article</type><title>Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ismail, Teli Shaikh Emaran Shaikh ; Ramanand, Jaiprakash ; Mandhare, Rajshree Netram ; Bhangale, Chetan Suresh</creator><creatorcontrib>Ismail, Teli Shaikh Emaran Shaikh ; Ramanand, Jaiprakash ; Mandhare, Rajshree Netram ; Bhangale, Chetan Suresh</creatorcontrib><description>Various studies have reported that there has been a decrease in IL-6 level, C-reactive protein (CRP) level, and lower risk of death with the use of tocilizumab in patients with severe COVID-19 disease. [5] Therefore, cytokine storm has an important role in disease progression with the viral invasion of the cellular immunity. [...]immunomodulatory agents may play an important role in handling the immune response. Studies have reported there has been a decrease in IL-6 level, C-reactive protein (CRP) level, and lower risk of death with the use of tocilizumab in patients with severe COVID-19 disease. [6,7] Tocilizumab (Actemra®) is a recombinant IL-6 receptor monoclonal antibody which can specifically bind to the membrane-bound IL-6 receptor and soluble IL-6 receptor. [...]it inhibits signal transduction and prevents further damage due to immune response. [9] Despite so many studies, it is not claimed that tocilizumab has a positive therapeutic effect on COVID-19. [...]this study aims to assess the effect of tocilizumab on clinical outcomes in terms of death and discharge in patients who received tocilizumab at our institution.</description><identifier>ISSN: 2320-4672</identifier><identifier>EISSN: 2231-3206</identifier><identifier><![CDATA[DOI: 10.5455/njppp.<SERIAL_printed_date>2021</SERIAL_printed_date>.11.05156<SERIAL_printed_date>2021</SERIAL_printed_date>0506<SERIAL_printed_date>2021</SERIAL_printed_date>]]></identifier><language>eng</language><publisher>Surat: Association of Physiologists, Pharmacists & Pharmacologists</publisher><subject>Arthritis ; Clinical outcomes ; Comorbidity ; Coronaviruses ; COVID-19 ; Cytokine storm ; Dehydrogenases ; Demographics ; Disease ; Hypertension ; Immunosuppressive agents ; Laboratories ; Monoclonal antibodies ; Mortality ; Observational studies ; Pandemics ; Severe acute respiratory syndrome coronavirus 2 ; Signal transduction ; Statistical analysis</subject><ispartof>National journal of physiology, pharmacy and pharmacology, 2021-01, Vol.11 (9), p.1060-1063</ispartof><rights>2021. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Ismail, Teli Shaikh Emaran Shaikh</creatorcontrib><creatorcontrib>Ramanand, Jaiprakash</creatorcontrib><creatorcontrib>Mandhare, Rajshree Netram</creatorcontrib><creatorcontrib>Bhangale, Chetan Suresh</creatorcontrib><title>Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study</title><title>National journal of physiology, pharmacy and pharmacology</title><description>Various studies have reported that there has been a decrease in IL-6 level, C-reactive protein (CRP) level, and lower risk of death with the use of tocilizumab in patients with severe COVID-19 disease. [5] Therefore, cytokine storm has an important role in disease progression with the viral invasion of the cellular immunity. [...]immunomodulatory agents may play an important role in handling the immune response. Studies have reported there has been a decrease in IL-6 level, C-reactive protein (CRP) level, and lower risk of death with the use of tocilizumab in patients with severe COVID-19 disease. [6,7] Tocilizumab (Actemra®) is a recombinant IL-6 receptor monoclonal antibody which can specifically bind to the membrane-bound IL-6 receptor and soluble IL-6 receptor. [...]it inhibits signal transduction and prevents further damage due to immune response. [9] Despite so many studies, it is not claimed that tocilizumab has a positive therapeutic effect on COVID-19. [...]this study aims to assess the effect of tocilizumab on clinical outcomes in terms of death and discharge in patients who received tocilizumab at our institution.</description><subject>Arthritis</subject><subject>Clinical outcomes</subject><subject>Comorbidity</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytokine storm</subject><subject>Dehydrogenases</subject><subject>Demographics</subject><subject>Disease</subject><subject>Hypertension</subject><subject>Immunosuppressive agents</subject><subject>Laboratories</subject><subject>Monoclonal antibodies</subject><subject>Mortality</subject><subject>Observational studies</subject><subject>Pandemics</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Signal transduction</subject><subject>Statistical analysis</subject><issn>2320-4672</issn><issn>2231-3206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVTc1KAzEQDqJg0b7DgOduk-xma6UIpbZYEAQVr0u6GWmW7SYmsxV9Bh_ExzSCRw92Lt98fH-MfQmeqUKpcdd477PZ4_JhPb-rfLAdoamMJryWXIrZ-C8lEyLjSqjywBxX_NDIERtImYtRLnl5nP6Eo6KcyFM2jLHh6aaFSI4B-1y0trO1bsH1VLsdgu2gdsF1em9DH8HYiDoieE0WO4pAAdOEgTdLWyBX29Z-9Du9AU2gwaBJbT_64v55fQNbF70l3V7BHAJSSBRrsnsEt4kY9qk1TbUQqTfv5-zkRbcRh794xi5Wy6fF7cgH99pjpKpxfUj2WEk1kXIq8_wy_5_rGzcvjyY</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Ismail, Teli Shaikh Emaran Shaikh</creator><creator>Ramanand, Jaiprakash</creator><creator>Mandhare, Rajshree Netram</creator><creator>Bhangale, Chetan Suresh</creator><general>Association of Physiologists, Pharmacists & Pharmacologists</general><scope>04Q</scope><scope>04S</scope><scope>04W</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20210101</creationdate><title>Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study</title><author>Ismail, Teli Shaikh Emaran Shaikh ; Ramanand, Jaiprakash ; Mandhare, Rajshree Netram ; Bhangale, Chetan Suresh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_25722923383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Arthritis</topic><topic>Clinical outcomes</topic><topic>Comorbidity</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytokine storm</topic><topic>Dehydrogenases</topic><topic>Demographics</topic><topic>Disease</topic><topic>Hypertension</topic><topic>Immunosuppressive agents</topic><topic>Laboratories</topic><topic>Monoclonal antibodies</topic><topic>Mortality</topic><topic>Observational studies</topic><topic>Pandemics</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Signal transduction</topic><topic>Statistical analysis</topic><toplevel>online_resources</toplevel><creatorcontrib>Ismail, Teli Shaikh Emaran Shaikh</creatorcontrib><creatorcontrib>Ramanand, Jaiprakash</creatorcontrib><creatorcontrib>Mandhare, Rajshree Netram</creatorcontrib><creatorcontrib>Bhangale, Chetan Suresh</creatorcontrib><collection>India Database</collection><collection>India Database: Business</collection><collection>India Database: Science & Technology</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>National journal of physiology, pharmacy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ismail, Teli Shaikh Emaran Shaikh</au><au>Ramanand, Jaiprakash</au><au>Mandhare, Rajshree Netram</au><au>Bhangale, Chetan Suresh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study</atitle><jtitle>National journal of physiology, pharmacy and pharmacology</jtitle><date>2021-01-01</date><risdate>2021</risdate><volume>11</volume><issue>9</issue><spage>1060</spage><epage>1063</epage><pages>1060-1063</pages><issn>2320-4672</issn><eissn>2231-3206</eissn><abstract>Various studies have reported that there has been a decrease in IL-6 level, C-reactive protein (CRP) level, and lower risk of death with the use of tocilizumab in patients with severe COVID-19 disease. [5] Therefore, cytokine storm has an important role in disease progression with the viral invasion of the cellular immunity. [...]immunomodulatory agents may play an important role in handling the immune response. Studies have reported there has been a decrease in IL-6 level, C-reactive protein (CRP) level, and lower risk of death with the use of tocilizumab in patients with severe COVID-19 disease. [6,7] Tocilizumab (Actemra®) is a recombinant IL-6 receptor monoclonal antibody which can specifically bind to the membrane-bound IL-6 receptor and soluble IL-6 receptor. [...]it inhibits signal transduction and prevents further damage due to immune response. [9] Despite so many studies, it is not claimed that tocilizumab has a positive therapeutic effect on COVID-19. [...]this study aims to assess the effect of tocilizumab on clinical outcomes in terms of death and discharge in patients who received tocilizumab at our institution.</abstract><cop>Surat</cop><pub>Association of Physiologists, Pharmacists & Pharmacologists</pub><doi><![CDATA[10.5455/njppp.<SERIAL_printed_date>2021</SERIAL_printed_date>.11.05156<SERIAL_printed_date>2021</SERIAL_printed_date>0506<SERIAL_printed_date>2021</SERIAL_printed_date>]]></doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2320-4672 |
| ispartof | National journal of physiology, pharmacy and pharmacology, 2021-01, Vol.11 (9), p.1060-1063 |
| issn | 2320-4672 2231-3206 |
| language | eng |
| recordid | cdi_proquest_journals_2572292338 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Arthritis Clinical outcomes Comorbidity Coronaviruses COVID-19 Cytokine storm Dehydrogenases Demographics Disease Hypertension Immunosuppressive agents Laboratories Monoclonal antibodies Mortality Observational studies Pandemics Severe acute respiratory syndrome coronavirus 2 Signal transduction Statistical analysis |
| title | Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T16%3A15%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcome%20in%20coronavirus%20disease%20patients%20treated%20with%20tocilizumab%20at%20a%20dedicated%20COVID%20hospital:%20A%20retrospective%20observational%20study&rft.jtitle=National%20journal%20of%20physiology,%20pharmacy%20and%20pharmacology&rft.au=Ismail,%20Teli%20Shaikh%20Emaran%20Shaikh&rft.date=2021-01-01&rft.volume=11&rft.issue=9&rft.spage=1060&rft.epage=1063&rft.pages=1060-1063&rft.issn=2320-4672&rft.eissn=2231-3206&rft_id=info:doi/10.5455/njppp.%3CSERIAL_printed_date%3E2021%3C/SERIAL_printed_date%3E.11.05156%3CSERIAL_printed_date%3E2021%3C/SERIAL_printed_date%3E0506%3CSERIAL_printed_date%3E2021%3C/SERIAL_printed_date%3E&rft_dat=%3Cproquest%3E2572292338%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2572292338&rft_id=info:pmid/&rfr_iscdi=true |